

Figure 1  
In Vitro response of CCRF-CEM Lymphoblastic T Cell Leukemia Cells Treated with Compound A  
in the Absence or Presence of rhTpo, rhEpo or rhG-CSF




Figure 2  
In Vitro Response of K562 Chronic Myelogenous Leukemia Cells treated with Compound A  
in the Absence or Presence of rhTpo, rhEpo or rhG-CSF




Figure 3  
In Vitro Response of MOLT-4 Acute Lymphoblastic T Cell Leukemia Cells Treated with Compound A  
in the Absence or Presence of rhTpo, rhEpo or rhG-CSF




Figure 4  
In Vitro Response of RPMI-8226 Plasmacytoma Cells Treated with Compound A  
in the Absence or Presence of rhTpo, rhEpo or rhG-CSF

